Cue Biopharma, Inc.
CUE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $9,287 | $5,490 | $1,245 | $14,941 |
| % Growth | 69.2% | 341% | -91.7% | – |
| Cost of Goods Sold | $0 | $38,097 | $0 | -$1,778 |
| Gross Profit | $9,287 | -$32,607 | $1,245 | $16,719 |
| % Margin | 100% | -593.9% | 100% | 111.9% |
| R&D Expenses | $36,295 | $40,802 | $38,578 | $41,347 |
| G&A Expenses | $14,585 | $16,680 | $16,169 | $17,307 |
| SG&A Expenses | $14,585 | $16,680 | $16,169 | $17,307 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$93 | -$37,940 | -$277 | $1,778 |
| Operating Expenses | $50,787 | $19,542 | $54,470 | $60,431 |
| Operating Income | -$41,500 | -$52,149 | -$53,225 | -$43,712 |
| % Margin | -446.9% | -949.9% | -4,275.1% | -292.6% |
| Other Income/Exp. Net | $826 | $1,416 | $215 | $46 |
| Pre-Tax Income | -$40,674 | -$50,733 | -$53,010 | -$43,666 |
| Tax Expense | $0 | $0 | $0 | $495 |
| Net Income | -$40,674 | -$50,733 | -$53,010 | -$44,161 |
| % Margin | -438% | -924.1% | -4,257.8% | -295.6% |
| EPS | -0.72 | -1.11 | -1.49 | -1.41 |
| % Growth | 35.1% | 25.5% | -5.7% | – |
| EPS Diluted | -0.72 | -1.11 | -1.49 | -1.41 |
| Weighted Avg Shares Out | 56,328 | 45,755 | 35,649 | 31,285 |
| Weighted Avg Shares Out Dil | 56,328 | 45,755 | 35,649 | 31,285 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,622 | $2,661 | $928 | $46 |
| Interest Expense | $796 | $1,245 | $714 | $0 |
| Depreciation & Amortization | $2,350 | $3,436 | $1,806 | -$1,778 |
| EBITDA | -$37,528 | -$46,052 | -$50,491 | -$45,444 |
| % Margin | -404.1% | -838.8% | -4,055.5% | -304.1% |